H.C. Wainwright Reiterates Their Buy Rating on OncoSec Medical (ONCS)

By Jason Carr

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on OncoSec Medical (NASDAQ: ONCS) today and set a price target of $4. The company’s shares closed yesterday at $1.66.

Selvaraju commented:

“Our price target is derived from a market value of $260M for OncoSec, which includes a discounted cash flow-based asset value for ImmunoPulse IL-12, with 15% discount rate, 0% terminal growth rate and 30% probability of success.”

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -7.7% and a 28.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on OncoSec Medical is a Moderate Buy with an average price target of $4.50, which is a 171.1% upside from current levels. In a report issued on October 15, Maxim Group also maintained a Buy rating on the stock with a $5 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $2.95 and a one-year low of $1.04. Currently, OncoSec Medical has an average volume of 1.08M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications.